Summary Roivant Sciences' stock is undervalued with a market cap of $8.37 billion and $6 billion in cash.
Bram De Haas is a journalist who writes for Seeking Alpha, a platform focused on investment research and analysis. Bram covers a wide range of topics in the finance and investment space, providing insights and analysis on various companies, acquisitions, and market trends.